All News

Although involvement of a cardiologist for heart failure has been associated with reduced rates of in-hospital mortality, not all patients see a cardiologist when hospitalized, according to the investigators.

Many workers don’t advertise their level of loneliness, nor do they know the impact of loneliness on their well-being.

Exclusions of medication are often focused on high-cost specialty formularies, resulting in fewer options for patients who need them.

Marlo Blazer, PharmD, BCOP, discusses the collaborative nature of the pharmacist's role within the oncology care team.

An animal study shows that early-life stress may increase risk-taking behaviors in adulthood; in humans, this could translate to risk of substance use disorder.

Patients with uncontrolled chronic obstructive pulmonary disease and type 2 inflammation had significantly better lung function at least a year into dupilumab regimen.

Nacre may combat cortical bone loss and improve bone strength to reduce risk of fragility fractures.

These findings could make a significant difference in treating patients with Barth syndrome, which is an incurable genetic disease.

Neuroimaging showed that people who lacked sleep had altered risk-taking behaviors.

There is a great need to protect families and children that are commercially insured following the COVID-19 pandemic.

Further research is necessary to better understand the development and factors that contribute to CBC after PBC treatment.

Drug reaction with eosinophilia and systemic symptoms can start as a rash and quickly progress, affecting the internal organs and requiring hospitalization, even resulting in death.

Melatonin is not fully regulated by the FDA, and there are concerns about children taking the supplement due to associated risks, such as dependency and overdose.

By strengthening the continent's health care infrastructure, promoting local vaccine production, and facilitating global collaborations, the grant represents an important milestone toward better health care for all Africans.

Patients hospitalized for traumatic brain injury have different brain injury biomarkers and rates of glucose variation.

This is KRP203’s second Orphan Drug Designation and it is the only S1P receptor modulator being developed as an adjunctive and maintenance treatment for blood cancers.

This innovation could be useful for optimizing the collaboration between patients with asthma and their health care providers through remote telemedicine consultations.

The study authors are encouraged by the findings, noting that LIMS with algorithmic-based classification can aid in early and accurate diagnosis of skin cancer, improving patient prognosis.

No significant demographic or phenotypic differences were found between HLA-DQA1*05 carriers versus non-carriers, in either treatment group.

In addition to predicting breast cancer outcomes, the AI tool can help determine effective treatment options in patients, sparing them from unnecessary treatments.

Individuals treated with remibrutinib demonstrated symptom control improvement in week 2 of the trial

Belantamab mafodotin (Blenrep; GlaxoSmithKline) demonstrated that, when combined with bortezomib and dexamethasone (BorDex), the time to disease progression or death was extended.

This FDA clearance comes about 11 months after another clearance for appliances to treat mild-to-moderate obstructive sleep apnea (OSA)—the first clearance for oral appliances to treat OSA with supplemental therapies.

Combination prevention strategies reduced the number of new HIV infections among gay and bisexual men who have sex with men; however, improvement of current methods is needed to meet the 2025 and 2030 reduction goals.

Kirollos Hanna, PharmD, BCPS, BCOP, FACC, discusses the multifaceted involvement of oncology pharmacists in various aspects of patient care.

In this episode, we spoke with Dr. Christina Madison, founder and CEO of The Public Health Pharmacist, about why abortion access and reproductive care are public health issues.

Although vaccination status and the severity of COVID-19 infection were not correlated, the timing of vaccine administration influenced whether patients had severe COVID-19 infection.

In a phase 3 trial, none of the patients receiving nirogacestat reached median progression-free survival, indicating that it may effectively reduce disease progression.